Pharma patent licensing surge falters
High asset valuations and a loss of momentum in the oncology space seem to be behind a sharp fall in transactions
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.